Compare

ABIVAX Société Anonyme/€ABVX

1D1W1M3M6MYTD1Y5YMAX

About ABIVAX Société Anonyme

Abivax Société Anonyme is a clinical-stage biotechnology company headquartered in Paris, France, with a research center in Montpellier and a U.S. office in Waltham, Massachusetts. Founded in December 2013, the company focuses on developing therapeutics that modulate the immune response to treat chronic inflammatory diseases. Its lead drug candidate, obefazimod (formerly ABX464), is in Phase 3 clinical trials for moderately to severely active ulcerative colitis and is being prepared for a Phase 2a trial in Crohn's disease. Abivax collaborates closely with the French National Center for Scientific Research (CNRS), the Institut Curie, and the University of Montpellier. In 2015, the company raised €57.7 million in its initial public offering on Euronext Paris, and in October 2023, it raised €232.3 million through an IPO on the Nasdaq Global Market.
Ticker
€ABVX
Sector
Health
Primary listing
PAR
Employees
98
Headquarters
Paris, France
Website
www.abivax.com

ABVX Metrics

BasicAdvanced
€6.9B
-
-€5.18
-0.25
-

What the Analysts think about ABVX

Analyst ratings (Buy, Hold, Sell) for ABIVAX Société Anonyme stock.
Analyst projections of the future price of ABIVAX Société Anonyme stock.

Bulls say / Bears say

In the 44-week Phase 3 maintenance trial, obefazimod achieved clinical remission in 50.8% and 51.3% of patients at the two doses, versus 10.4% on placebo, and met key secondary endpoints. The results point to strong potential in ulcerative colitis. (Reuters, Abivax)
Abivax says its FDA pre-NDA meeting produced constructive feedback and alignment on its planned application strategy. It remains on track to file for ulcerative colitis by the end of 2026, a key step towards a potential launch. (Abivax)
Cash and short-term investments, plus net proceeds from the July share offering, are expected to fund operations into Q4 2029. That gives Abivax substantial scope to prepare a US launch and continue its Crohn’s disease programme without near-term financing pressure. (Abivax)
The maintenance trial recorded several malignancies, including four non-melanoma skin cancers in the higher-dose group. Although investigators did not consider the cases clearly treatment-related, the findings fuelled safety concerns and a sharp share-price fall. (CNBC, BioPharma Dive)
The July financing issued 7.36 million new ADSs and raised $920 million gross. The enlarged cash balance improves financial security, but issuing new shares dilutes existing holders. (Abivax)
The investment case is concentrated in obefazimod, which CNBC described as Abivax’s only drug asset. Crohn’s disease trial results are not expected until mid-2027, leaving the company reliant on its ulcerative colitis candidate and its regulatory path in the meantime. (CNBC, Abivax)
Data summarised monthly by Lightyear AI. Last updated on 22 Oct 2026.

ABVX Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

ABVX Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Funds containing ABVX

AllEURUSDGBP
Funds
Fund name
Fund size
€ABVX weighting
iShares EURO STOXX Mid€DJMC
€595M0.76%
iShares EURO STOXX Mid Cap£DJMC
€595M0.76%
iShares STOXX Europe Mid 200€EXSD
€610M0.37%
iShares STOXX Europe 600 Health Care€EXV4
€709M0.35%
iShares Nasdaq US Biotechnology£BTEK
$1.1B0.32%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.